Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06451497 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer, sponsored by Zumutor Biologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT06451497 is a Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Zumutor Biologics. The registered enrollment target is 33 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06451497, a Phase 1 study of Prostate Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Zumutor Biologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Conditions Studied
Interventions
- BIOLOGICAL ZM008
Study Locations (3)
Texas
- NEXT Oncology - Austin
- NEXT Oncology - San Antonio
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06451497
The ClinicalTrials.gov registry entry for NCT06451497 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Zumutor Biologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZM008 is the first listed.
NCT06451497 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06451497 about?
NCT06451497 is a clinical study titled "Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
What is the current status of trial NCT06451497?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2024-05-22. Estimated completion is 2027-04.
What conditions does trial NCT06451497 study?
This clinical trial studies the following conditions: Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06451497?
The interventions under investigation include: ZM008 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06451497?
This trial is sponsored by Zumutor Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06451497 being conducted?
This trial has 3 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.